ECOG PCO-RL: E2607 - A Phase II Trial of Dasatinib in Patients with Unresectable Locally Advance or Stage IV Mucosal, Acral and Solar Melanomas

Project: Research project

Project Details

StatusFinished
Effective start/end date5/1/09 → 4/30/16

Funding

  • Frontier Science and Technology Research Foundation (PCOE2607-00)
  • Bristol-Myers Squibb Company (PCOE2607-00)